Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $505.7 million.

  • Kymera Therapeutics' Cash & Current Investments fell 805.28% to $505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.7 million, marking a year-over-year decrease of 805.28%. This contributed to the annual value of $488.7 million for FY2024, which is 3037.31% up from last year.
  • Per Kymera Therapeutics' latest filing, its Cash & Current Investments stood at $505.7 million for Q3 2025, which was down 805.28% from $665.4 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Cash & Current Investments ranged from a high of $709.0 million in Q1 2025 and a low of $333.5 million during Q1 2021
  • Its 5-year average for Cash & Current Investments is $464.2 million, with a median of $442.4 million in 2021.
  • Per our database at Business Quant, Kymera Therapeutics' Cash & Current Investments surged by 48898.0% in 2021 and then plummeted by 2574.83% in 2023.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Cash & Current Investments stood at $442.4 million in 2021, then dropped by 7.97% to $407.2 million in 2022, then decreased by 7.93% to $374.9 million in 2023, then surged by 30.37% to $488.7 million in 2024, then rose by 3.47% to $505.7 million in 2025.
  • Its Cash & Current Investments was $505.7 million in Q3 2025, compared to $665.4 million in Q2 2025 and $709.0 million in Q1 2025.